A detailed how-to guide on ophthalmic marketing could easily fill hundreds of Healio blogs. (Indeed, SLACK/OSN published my first book, which was dedicated to ophthalmic marketing, 27 years ago. Looking at how primitive this book is today is an indication of how fast the field has changed since I wrote it.) To get started, let’s look at some of the numbers that should guide your decisions. As a first step in assessing your situation, prepare a graph for the past 12 or more months of the number of month-by-month new (Read more...)
Valeant to acquire Bausch + Lomb for $8.7 billion
Valeant Pharmaceuticals has agreed to purchase Bausch + Lomb for $8.7 billion in cash, according to a joint news release from the companies.Under the agreement, Bausch + Lomb will keep its name and function as a division of Valeant, and Valeant’s ophthalmology holdings will be folded into the Bausch + Lomb division, the release said.
Alcon launches JETREA in Denmark and Sweden
ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA in Denmark and Sweden, the third and fourth European markets…
Study Backs Benefits of Omega-3s for Dry Eye Syndrome
Taking oral omega-3 fatty acids for 30 days significantly reduces the symptoms of dry eye syndrome, a report online May 3 in Ophthalmology demonstrates. Reuters Health Information
RVO: Reading Speed Improves With Ranibizumab Injections
Ranibizumab therapy makes a functional difference for patients with retinal vein occlusion, researchers have found. Medscape Medical News
Patients With Macular Degeneration at Increased Death Risk
Age-related macular degeneration was associated with a higher risk for death related to circulatory disease and all-cause mortality in a long-term follow-up of the AREDS study. Medscape Medical News